Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
-
A3178 AN-2728Summary: PDE4 inhibitor,anti-inflammatory compound
-
B1386 MilrinoneTarget: Phosphodiesterases (PDEs)Summary: PDE-3 inhibitor
-
B1165 Pimobendan hydrochlorideSummary: Selective inhibitor of PDE3
-
N1705 IcariinSummary: PDE5 inhibitor
-
B2276 VinpocetineTarget: Phosphodiesterases (PDEs)Summary: PDE inhibitor
-
B6073 Sildenafil mesylateSummary: PDE5 inhibitor
-
C3266 Amino TadalafilSummary: analog of tadalafil, a potent inhibitor of phosphodiesterase 5
-
C3510 MBCQSummary: cGMP-specific phosphodiesterase PDE V inhibitor
-
C4796 EggmanoneSummary: selective inhibitor of PDE4
-
C4686 2-Acetamidophenyl 5-chloro-2-nitrophenyl sulfideSummary: phosphodiesterase 7 (PDE7) inhibitor